As of 10:30 a.m. on October 26, GC Pharma is trading at 277,500 KRW, up 3.16% from the previous day. The trading volume is 523,034 shares, which is 22.87% of the previous day's trading volume. GC Pharma is known as a pharmaceutical company specializing in blood products and vaccines.


On October 23, Lee Hyerin, a researcher at KTB Investment & Securities, stated, "The signing of the COVID-19 vaccine CMO agreement with CEPI (Coalition for Epidemic Preparedness Innovations) is a surprise issue. More detailed CMO contracts with multiple global pharmaceutical companies are expected in the future. While it is difficult to guarantee long-term sustainability for the COVID-19 vaccine business, it is expected to serve as a cash cow in the short to medium term." She announced a target price of 300,000 KRW for GC Pharma.


Over the past five days, individual investors have been net sellers of 146,284 shares of GC Pharma, while foreign investors and institutions have been net buyers of 47,596 shares and 91,027 shares, respectively.


Hot Picks Today

"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ① "Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①

※ Source: AI investment assistant AI Rassiro


※ This article was automatically generated in real time by a news automation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.



한글 기사 보기
This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing